Catalog Advanced Search

Search by Category
Search by Format
Search by Type
Sort By
Search by Favorites
Search by Keyword
Search by Category
Search by Format
Search by Type
Search by Speakers
Credits Offered
Search in Packages
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Favorites
Search by Keyword
Sort By

  • Promoting AP involvement in Clinical Research: Highlighting Pathways in Community and Academic Settings
    Contains 3 Component(s)

    Learn how advanced practitioners (APs) can integrate clinical research into their daily practice and explore the various roles they can take on, such as principal or co-investigator. You'll also gain practical tips and resources to help you get started in research within community and academic settings.

    Tune to the APSHO Research and Quality Improvement Forum for a webinar on Promoting AP involvement in Clinical Research: Highlighting Pathways in Community and Academic Settings with an expert panel of research advanced practitioners from a diverse group of organizations.

    • Career Background: Journey of an oncology APP in clinical research.
    • Daily Schedule: Integrating research into a typical workday.
    • Tips and Resources: Practical tips for APPs to get involved in research.


    The content of this webinar is presented by APSHO but does not necessarily reflect the views, opinions, or ideas of APSHO as an organization. The content has not been peer-reviewed and is not eligible for continuing education credits. APSHO is not responsible for any medical decisions made by attendees based on the information provided in this presentation. Any issues, concerns, or questions regarding the presentation should be directed to info@apsho.org.  

    Christa Braun-Inglis (Moderator)

    DNP, APRN-Rx, FNP-BC, AOCNP

    University of Hawaii Cancer Center

    Christa Braun-Inglis was the first oncology nurse practitioner in the state of Hawaii. Dr. Braun-Inglis has been instrumental on the local and national level in expanding the role of advanced practice providers (APPs) in clinical trials. She has also advocated for cancer clinical trials in the community setting and diverse patient enrollment in clinical trials. With over 25 years of oncology nursing experience, she holds a dual role as both a nurse practitioner and an assistant researcher at the University of Hawaii Cancer Center in Honolulu, Hawaii. She is also a clinical faculty member at the University of Hawaii School of Nursing. Through her efforts, the National Cancer Institute (NCI) revised their policies in 2021, empowering APPs to fully exercise their credentials and enroll patients in supportive care trials. In 2023, she received the National Cancer Institute’s Director’s Award. In addition, she is also the current Chair of the Research and Quality Improvement committee of APSHO.


    Christa Braun-Inglis has no relevant financial relationships to disclose.

    Lisa A. Kottschade

    APRN, MSN, CNP, FAPO, APSHO President

    Mayo Clinic

    Ms. Lisa A. Kottschade is an Associate Professor of Oncology and a Nurse Practitioner in the Melanoma and Cutaneous Oncology and Immunotherapy Toxicity Clinics at Mayo Clinic. Recently she was named the Chair of Research Committee for the Office of NP/PA in Rochester. She is the current President of APSHO as well as leads the Alliance Oncology Nursing Committee. Her clinical and research interests include those in the field of melanoma including its treatment and management of side effects from therapy with a special focus on those related to Immune Checkpoint Inhibitors.

    Lisa A. Kottschade has no relevant financial relationships to disclose.

    Mee-young Lee

    MSN, ANP-BC, AOCNP

    Dana-Farber Cancer Institute

    Mee-young Lee is a nurse practitioner with over 25 years of oncology experience. She earned her MSN from the University of Pennsylvania in 2006 and has held clinical roles at Beth Israel Deaconess Medical Center, Northwell Health, and St. Francis Heart Hospital. She currently practices at Dana-Farber Cancer Institute, specializing in thoracic oncology. Mee-young is also an active member of the Research and Quality Improvement Committee of the Advanced Practitioner Society for Hematology and Oncology (APSHO).

    Mee-young Lee has no relevant financial relationships to disclose.

    Ashley Springer

    MSN, AGPCNP-BC, APRN-Rx

    Hawaii Cancer Care

    Ashley received a Master of Science in nursing degree from University of Hawaii at Manoa. She has been a nurse practitioner in medical oncology and hematology for over 10 years. Ashley is a member of APSHO’s Research and Quality Initiative Task Force. She currently serves as co-chair for the CCDR/Symptom management disease site working group and member of the thoracic and hematology disease site working groups at the University of Hawaii Cancer Center. She has served as site PI for several CCDR/Symptom management clinical trials as well as serving as a non-physician investigator on cooperative group and industry therapeutic clinical trials. She also maintains an active role precepting nurse practitioner students.

    Ashley Springer has no relevant financial relationships to disclose.

  • Fertility Preservation in Radiation Oncology: Counseling and Options
    Contains 3 Component(s)

    Learn about fertility preservation in radiation oncology, including impacts, strategies, counseling, collaboration, and evidence-based guidelines.

    Tune to the APSHO Radiation Oncology APP Network for a webinar on Fertility Preservation in Radiation Oncology: Counseling and Options with Emery Bergey, MBA, MSN, APRN, AGCNS-BC, OCN. 

    • Understand the impact of radiation on fertility
    • Identify fertility preservation strategies
    • Enhance counseling and shared decision-making skills
    • Navigate multidisciplinary collaboration and referral pathways
    • Apply evidence-based guidelines and institutional protocols

    The content of this webinar is presented by APSHO but does not necessarily reflect the views, opinions, or ideas of APSHO as an organization. The content has not been peer-reviewed and is not eligible for continuing education credits. APSHO is not responsible for any medical decisions made by attendees based on the information provided in this presentation. Any issues, concerns, or questions regarding the presentation should be directed to info@apsho.org.  

    Emery Bergey (Moderator)

    MBA, MSN, APRN, AGCNS-BC, OCN

    Moffitt Cancer Center

    Emery Bergey, MBA, MSN, APRN, AGCNS-BC, OCN, is a clinical nurse specialist and advanced practice provider in the department of Radiation Oncology at Moffitt Cancer Center in Tampa, Florida. She holds multiple advanced degrees and certifications, including a Master of Science in Nursing Education, an MBA, and a post-master’s certificate in advanced practice nursing. Emery has extensive experience in oncology nursing, Lean Six Sigma, and trauma-informed care. She has worked as a lead RN case manager at the University of Florida Proton Therapy Institute and is a National Innovation and Entrepreneurship Fellow. Emery is dedicated to advancing holistic care for adolescent and young adult oncology patients and advocating for oncofertility care.

  • Manuscript Writing 101
    Contains 2 Component(s)

    This module assists the learner to develop a manuscript for submission. The learner will learn to identify topics and develop manuscripts with useful tips provided by the faculty.

    Manuscript Writing 101 covers essential steps from choosing a research topic to journal submission and peer review responses. This course was designed to help Advanced Practitioners master scientific writing, providing the tools and insights needed for successful publication. It is ideal for both beginners and those looking to refine their skills.

    At the conclusion of this activity, participants will be able to:

    • Discuss choosing the right research topic and journal
    • Understand the manuscript submission process
    • Navigating peer reviews and revisions
    • Avoiding predatory journals
    • Amanda Brink, DNP, APRN, FNP-BC, AOCNP
    • Sandra Cuellar, PharmD, BCOP
    • Cara Fleming, AGPCNP-BC, AOCNP
    • Carolyn Grande, CRNP, AOCNP, FAPO
    • Amber Koehler, PA-C
    • Heather Lewin, MSN, APRN
    • Gayathri Moorthy, PhD, APRN, AOCNP
    • Nancy Nix, PharmD, BCPS, BCOP
    • Anshika Singh, PharmD
    • Gabriele Urschel, DNP, RN, FNP-C, AOCNP
    • Constance Visovsky, PHD, RN, ACNP, FAAN
    • Amelia Wodzinski, RN, CRNP, AOCNP
    • Wendy Vogel, MSN, FNP, AOCNP, FAPO
    • Heather Koniarczyk, MSN, APRN-CNP, AOCNP, FAPO

    Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP

    Clinical Associate Professor, Clinical Oncology Pharmacist

    University of Illinois at Chicago (UIC), UI Health

    Dr. Sandra Cuellar is a Clinical Associate Professor in the Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy and a clinical oncology pharmacist at UI Health. She received her PharmD degree from the University of Illinois at Chicago College of Pharmacy and then completed a Pharmacy Practice Residency at University of Kentucky Chandler Medical Center. Following her residency, she completed a specialty oncology residency at MD Anderson Cancer Center in Houston. Dr. Cuellar is the director of the oncology residency program and chair of the IRB at UI Health. Dr. Cuellar is an editor at large for the Journal of Hematology Oncology Pharmacy and an invited lecturer to national organizations, including HOPA, ASHP, ACCP, ACCC, and AMCP. In addition, Dr. Cuellar was recently appointed to be a member of the ASHP Commission on Credentialing and past chair of the industry relation council for the Hematology Oncology Pharmacy Association. 

  • Clinical Oncogenomics for the Advanced Practitioner
    Contains 5 Component(s)

    This course covers the basics of cancer biology and genetics, including cancer characteristics, carcinogenesis, oncogenes, tumor suppressor genes, and cellular signaling pathways. It also addresses genetic testing for hereditary cancer syndromes and tumor genomic profiling, with insights into future developments, report information, and somatic variant–drug pairs.

    This course provides a comprehensive exploration of cancer biology and genetics. It delves into the characteristics of cancer, the mechanisms of carcinogenesis, and the roles of oncogenes and tumor suppressor genes. Learners will gain insights into cellular signaling pathways and the genetic testing associated with hereditary cancer syndromes. The course also covers tumor genomic profiling, discussing its indications, various types, and future advancements. Additionally, it offers an in-depth look at the common information found in genomic reports and the interplay between somatic variants and drug pairs.

    This activity qualifies as Category II Continuing Medical Education (CME) for Physician Assistants. Category II CME activities include any medically related activity that enhances the role of a PA and has not been designated for Category I CME credit. It is the responsibility of the participant to log Category II CME hours in accordance with NCCPA guidelines.

  • Clinical Management and Toxicity Considerations of ADCs
    Contains 2 Component(s)

    Join Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP, for an in-depth webinar on the management and toxicity considerations for patients receiving antibody-drug conjugate (ADC) therapy.

    This webinar will explore:

      • Advanced toxicity prediction and proactive management strategies
      • Identification of adverse events and management best practices
      • Practical approaches to ADC therapy optimization
      • Patient education for optimizing quality of life while on treatment
      • The APP's role in the management of patients receiving ADCs


    This event was sponsored by Gilead, AstraZeneca, Astellas and Pfizer

    Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP

    Rutgers Cancer Institute

    Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP, is a nurse practitioner in the GU Medical Oncology Group at Rutgers Cancer Institute. In her role, she manages patients on chemotherapy, oral oncolytics, bio/immunotherapy, antibody-drug conjugates (ADCs), targeted therapies, and clinical trials, calling on her in-depth oncology-specific knowledge base for clinical decision capability. Ms. Kota initially joined Rutgers Cancer Institute as a nurse clinician in adult infusion and then transferred to the Stacy Goldstein Breast Cancer Center. She moved into her current role after graduating from the nurse practitioner program at Drexel University. Her nursing experience includes medical oncology in community, inpatient, and outpatient settings. Ms. Kota has been an author on several publications and is frequently engaged as an expert speaker in the identification and management of toxicities and adverse events from ADC therapy in oncology.

  • Molecular Architecture of ADCs: Targets, Linkers, and Payloads
    Contains 2 Component(s)

    Join Amber B. Clemmons, PharmD, BCOP, FHOPA, for an informative webinar on antibody-drug conjugate (ADC) molecular design principles.

    This webinar will explore:
      • Antibody targeting mechanisms
      • Linker technologies and their role in drug release
      • Payload selection and cytotoxic mechanism
      • How molecular design influences toxicity profiles
      • Patient selection criteria based on disease state and molecular targeting
      • The APP's role in managing patients on ADCs

     This event was sponsored by Gilead, AstraZeneca, Astellas and Pfizer.

    Amber B. Clemmons, PharmD, BCOP, FHOPA

    Wellstar-MCG Health

    Dr. Clemmons received her Doctor of Pharmacy degree from the University of Michigan College of Pharmacy, completed a University of Georgia College of Pharmacy Teaching Certificate during her PGY1 year at MCG Health/UGA, and PGY2 Hematology/Oncology Pharmacy residency at the University of North Carolina (UNC Hospitals and Clinics), Chapel Hill NC. She is currently a Clinical Professor at the University of Georgia College of Pharmacy and clinical pharmacy specialist for the adult bone marrow transplantation (BMT)/malignant hematology team at Wellstar-MCG Health. She is a highly active member of the Hematology Oncology Pharmacy Association (HOPA) and the American Society for Transplantation and Cellular Therapy (ASTCT) Pharmacy Special Interest Group (SIG), as well as a member of ASHP, GSHP, and the Georgia Cancer Center. Dr. Clemmons has received the ASTCT Pharmacy SIG New Practitioner of the Year Award (2014), Teacher of the Year Award at the UGA College of Pharmacy (2016), the HOPA New Practitioner Award (2017) and received HOPA fellow status (FHOPA) in 2022. Dr. Clemmons serves as the Residency Program Director for the UGA/Wellstar MCG Health Medical Center PGY2 Oncology Pharmacy program.

  • Top Dermatologic Toxicities from Cancer Therapy: Prevention and Early Intervention
    Contains 2 Component(s)

    Join Cara Norelli and Megan Bielawa, advanced practice providers who specialize in oncodermatology, to gain critical insights into managing dermatologic toxicities from cancer therapies. This webinar will equip you with the skills to recognize toxicities and understand the impact on patient well-being and treatment adherence and implement evidence-based prevention and management strategies.

    Learning Objectives:

      • Recognize common dermatologic toxicities in patients receiving anti-cancer therapy 
      • Understand the importance of dermatologic toxicities and the impact on patients’ quality of life and treatment adherence  
      • Describe evidence-based prevention and management strategies for skin-related adverse effects
      • Illustrate the role of advanced practice providers in monitoring, prevention, and patient education of dermatologic toxicities 
      • Understand best practices for patient reporting of negative skin outcomes


    This event was sponsored by Johnson & Johnson

    Megan Bielawa, DMSc, MS, PA-C

    Memorial Sloan Kettering Cancer Center

    Megan Bielawa is a board-certified physician assistant specializing in dermatology. She has been working in the field of dermatology for 7 years and specifically in oncodermatology for the past 5 years at Memorial Sloan Kettering Cancer Center in Hauppauge. She serves as a guest lecturer for the Hofstra University Physician Assistant Studies program where she developed the Dermatology for Patients of Color curriculum. She also serves as a mentor and clinical preceptor for PA students.

    Cara Norelli, MS, AGNP-C

    Memorial Sloan Kettering Cancer Center

    Cara Norelli is a board-certified adult nurse practitioner with 8 years of dermatology experience and is currently specializing in Oncodermatology at Memorial Sloan Kettering Cancer Center in Manhattan. She is compassionate about treating conditions related to various cancer therapies including rashes, hair changes and cancerous wounds.

  • Optimizing APP Utilization in Radiation Oncology: Metrics, Challenges, and Best Practices
    Contains 2 Component(s)

    Expert panel discussion highlighting practical solutions and best practices for current and future APPs in radiation oncology.

    The APSHO Radiation Oncology Committee brings you the APSHO Radiation Oncology APP Network: APP Utilization in Radiation Oncology: Metrics, Challenges, and Best Practices lead by an expert panel on the following key topics:

    • Successful Utilization Models and Challenges
    • Balancing Clinical and Administrative Roles
    • Performance Metrics and Quality Care Alignment
    • Professional Development and Career Growth
    • Navigating Regulatory and Institutional Hurdles

    The content of this webinar is presented by APSHO but does not necessarily reflect the views, opinions, or ideas of APSHO as an organization. The content has not been peer-reviewed and is not eligible for continuing education credits. APSHO is not responsible for any medical decisions made by attendees based on the information provided in this presentation. Any issues, concerns, or questions regarding the presentation should be directed to info@apsho.org.  

    Katie Bukolt MSN, APRN, FNP-C, AOCNP (Moderator)

    APP Area Manager-Dallas Sammons

    Texas Oncology/ US Oncology

    Kate Martin, PA-C

    Senior manager of APPs for the Department of Radiation Oncology

    Dana-Farber Brigham and Women's Cancer Center

    Maitry Patel, MBA, BSC, BHSc(PA), CCPA

    Manager of Clinical Operations

    University Hospitals in Cleveland, Ohio

    Molly Tate, APRN, FNP-C

    AP Supervisor of Radiation Oncology

    MD Anderson Cancer Center

  • Hematology, Oncology and Drug Updates: 2024
    Contains 2 Component(s)

    Tune in to stay updated with the latest advancements in hematology, oncology from the ASCO 2024 conference, and FDA drug approvals.

    Tune in to stay updated with the latest advancements in hematology, oncology from the ASCO 2024 conference, and FDA drug approvals.

    • Hematology Update from ASCO 2024: Discusses key findings in hematology, including new research and treatment approaches.
    • Solid Tumor Oncology Update from ASCO 2024: Covers the latest in solid tumor treatments and their clinical implications.
    • Drug Approval Updates: Reviews the newest drug approvals and their potential impact on patient care

    By watching this webinar, advanced practitioners will gain critical insights into the latest research, innovative treatments, and new drug approvals, enhancing their ability to provide cutting-edge care to patients.

    Katie Sellers (Moderator)

    MPAS, PA-C

    Texas Oncology, Dallas, TX

    No relevant financialrelationships to disclose

    Andrew Guinigundo (Moderator)

    MSN, RN, CNP, ANP-BC, FAPO

    Cincinnati Cancer Advisors, OH

    Speakers’ Bureau: Amgen, Astellas, AstraZeneca, GSK, Natera,Pfizer

    Consulting:Amgen, AstraZeneca

    Megan May (Moderator)

    PharmD, BCOP, FHOPA, FAPO

    Baptist Health Lexington, KY

    Advisory Board: Lilly, Genentech, Pfizer, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline

    Speakers’Bureau: Amgen, AstraZeneca

    Consulting:Amgen, Lilly

  • APSHO Cancer Therapy Prescribing Course
    Contains 20 Product(s)

    The Cancer Therapy Prescribing Course is a comprehensive, CE-accredited course for nurse practitioners, PAs, and pharmacists benchmarking the education that advanced practitioners need to safely prescribe cancer therapy. Topics include chemotherapy, targeted therapy, and immunotherapy prescribing best practices.

    The Cancer Therapy Prescribing Course is a comprehensive, CE-accredited course for nurse practitioners, PAs, and pharmacists benchmarking the education that advanced practitioners need to safely prescribe cancer therapy. Topics include chemotherapy, targeted therapy, and immunotherapy prescribing best practices.

    This course was developed by the Advanced Practitioner Society for Hematology and Oncology (APSHO). Any recommendations contained in this course reflect APSHO's or Harborside's judgement regarding the state of general knowledge and practice in the field as of the date of publication. The recommendations may not be appropriate for use in all circumstances. APSHO and Harborside neither represent nor guarantee that the practices described herein will, if followed, ensure safe and effective patient care. Every healthcare provider should make their own determination regarding specific safe and appropriate patient care practices, including drug dosages and indications, considering patient specific characteristics, institutional policies and procedures, personnel, and equipment. The provider should always consult the most recent prescribing/product information. Though APSHO and the content creators have applied a rigorous review process to produce an error-free module, inadvertent mistakes can occur during the writing/editing/proofreading process. Information is not guaranteed to be accurate, complete, or current. APSHO, its editors, authors and reviewers cannot be held responsible for any liability incurred as a consequence for the application of any of the contents of this course contents. Figures and tables are used as examples and are not meant to be all-inclusive, nor do they represent endorsement of any particular therapy or institution. Websites mentioned are provided for information only and the website hosts are responsible for their own content and availability.